Description: Cytonics corporation is a R&D biotech leader specializing in developing diagnostic and Alpha-2-Macroglobulin (A2M) therapies for osteoarthritis.
Cytonics is a biotechnology research and development company that specializes in developing diagnostics and therapeutics for osteoarthritis. Our flagship product was the Fibronectin-Aggrecan Complex Test (“FACT™”), which can detect cartilage damage due to osteoarthritis from samples of patients’ joint fluid. We licensed FACT™ to Synthes (acquired by Johnson & Johnson) in 2011, and it has been used by hundreds of physicians to diagnose and direct patients’ course of treatment.
Discovery of FAC as a biomarker for osteoarthritis led to the identification of a naturally-occurring blood protein, Alpha-2 Macroglobulin (A2M), which protects cartilage from degradation and can alleviate joint pain. We developed an autologous therapy (“APIC™”) based upon the function of A2M, which has sold directly to physicians by a national medical device distributor since 2015. Over 6,000 patients, ranging from the elderly to young athletes, have been treated to date. We are developing new A2M-based th
“The individuals above were not compensated in exchange for their testimonials. In addition, their testimonials should not be construed as and/or considered investment advice.”